课题基金 / 基金详情

SAFETY, TOLERABILITY, AND ANTIRETROVIRAL ACTIVITY OF DMP 266

SAFETY, TOLERABILITY, AND ANTIRETROVIRAL ACTIVITY OF DMP 266
DMP 266 的安全性、耐受性和抗逆转录病毒活性
批准号：
6246613
负责人：
JAMES S KAHN
金额：
$3.14万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1997
资助国家：
美国
项目状态：
已结题
起止时间：
1997-03-03 至 1997-11-30
来源：
https://reporter.nih.gov/project-details/6246613
关键词：
AIDS therapy CD4 molecule antiAIDS agent antiviral agents clinical research combination chemotherapy drug resistance drug screening /evaluation genotype human subject human therapy evaluation outcomes research pharmacokinetics protease inhibitor reverse transcriptase inhibitors virus load

项目摘要

项目成果

JAMES S KAHN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This is a randomized Phase I/II study of indinavir (protease inhibitor) and DMP266 (non-nucleoside RT inhibitor) in patients with CD4 cells between 100-500 and viral load> 20,000 copies/ML. Treatments will be evaluated by viral load, CD4 cell changes and pharmacokinetics. The objective of the study is to evaluate the safety, tolerability, anti-viral activity of DMP266 alone and in combination with indinavir and to characterize the development of resistance to DMP266 by genotypic change of resistant status.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Seek, Test, Treat and Retain strategies leveraging mobile health technologies
Adherence Improvement and Measurement- AIM- System. Challenge Topic 10-MH-101
Adherence Improvement and Measurement- AIM- System. Challenge Topic 10-MH-101
Randomized controlled trial embedded in an electronic health record
海外基金